drugset / Trial / NCT01565850
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA \< 50 copies/mL at Week 24.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-01
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cobicistat | Small molecule | 150 mg | Oral |
| Subject | D/C/F/TAF | Unknown | — | Oral |
| Comparator | Darunavir | Small molecule | 800 mg | Oral |
| Subject | FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily | Unknown | — | Oral |